Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration

Figure 3

Popliteal lymph node cell proliferative responses after nasal matrix metalloproteinase (MMP) peptide administration prior to (left) or after (right) adjuvant arthritis (AA) induction. Responses were measured 35 days after AA induction. The irrelevant peptides used were MBP72–85 or ovalbumin peptide, OVA323–339. Data are expressed as the mean stimulation index (SI) of three or four organs ± standard error of the mean. *P < 0.05.

Back to article page